Advances in nanomedicine for the treatment of ankylosing spondylitis

References

• Shaikh SA. Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc. 2007;51(4):249–260.18060011
   PubMedGoogle Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390. doi:10.1016/S0140-6736(07)60635-717448825
   PubMed Web of Science ®Google Scholar
• Dakwar E,  Reddy J, Vale FL, Uribe JS. A review of the pathogenesis of ankylosing spondylitis. Neurosurg Focus 2008;24(1):E2.
   Google Scholar
• Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway. Ann Rheum Dis. 1985;44(6):359–367. doi:10.1136/ard.44.6.3593160312
   PubMed Web of Science ®Google Scholar
• Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61–66. doi:10.1007/s00296-002-0237-412634937
   PubMed Web of Science ®Google Scholar
• Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol. 2014;57(1):44–51. doi:10.1016/j.molimm.2013.07.01323993278
   PubMed Web of Science ®Google Scholar
• Keidel S, Chen L, Pointon J, Wordsworth P. ERAP1 and ankylosing spondylitis. Curr Opin Immunol. 2013;25(1):97–102. doi:10.1016/j.coi.2012.11.00223452840
   PubMedGoogle Scholar
• Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella – the evidence. Clin Rheumatol. 2007;26(6):858–864. doi:10.1007/s10067-006-0488-717186116
   PubMed Web of Science ®Google Scholar
• Li Y, Wang P, Xie Z, et al. Whole genome expression profiling and signal pathway screening of MSCs in ankylosing spondylitis. Stem Cells Int. 2014;2014.
   Web of Science ®Google Scholar
• Sheehan NJ. The ramifications of HLA-B27. J R Soc Med. 2004;97(1):10–14. doi:10.1258/jrsm.97.1.1014702356
   PubMedGoogle Scholar
• Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today. 1990;11:137–142.2187471
   PubMedGoogle Scholar
• Ebringer R, Cooke D, Cawdell DR, Cowling P, Ebringer A. Ankylosing Spondylitis: Klebsiella and HL-A B27. Rheumatol Rehabil 1977;16(3):190–196.
   Google Scholar
• Eastmond C, Willshaw HE, Burgess SE, Shinebaum R, Cooke EM, Wright V. Frequency of faecal Klebsiella aerogenes in patients with ankylosing spondylitis and controls with respect to individual features of the disease. Ann Rheum Dis. 1980;39(2):118–123. doi:10.1136/ard.39.2.1186992718
   PubMedGoogle Scholar
• Hunter T, Harding GKM, Kaprove RE, Schroeder M-L. Fecal carriage of various Klebsiella and Enterobacter species in patients with active ankylosing spondylitis. Arthritis Rheum. 1981;24(1):106–108. doi:10.1002/(ISSN)1529-01317470165
   PubMedGoogle Scholar
• Morse HG, Morse HG, Rate RG, Bonnell MD. Increased recovery of Klebsiella from the gastrointestinal tract of Reiter’s syndrome and ankylosing spondylitis patients. Rheumatology. 1983;XXII(suppl_2):85–90. doi:10.1093/rheumatology/XXII.suppl_2.85
   Google Scholar
• Cuvelier C, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Rheumatology. 1988;XXVII(suppl_2):95–105. doi:10.1093/rheumatology/XXVII.suppl_2.95
   Google Scholar
• Martínez-González O, Cantero-Hinojosa J, Paule-Sastre P, Gómez-Magán JC, Salvatierra-Ríos D.> Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. Rheumatology. 1994;33(7):644–647. doi:10.1093/rheumatology/33.7.644
   Web of Science ®Google Scholar
• Tam L-S, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nature Rev Rheumatol. 2010;6:399. doi:10.1038/nrrheum.2010.7920517295
   PubMed Web of Science ®Google Scholar
• McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352(9134):1137–1140. doi:10.1016/S0140-6736(97)12004-99798608
   PubMed Web of Science ®Google Scholar
• Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002;14(4):337–341.12118164
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo‐controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–591. doi:10.1002/(ISSN)1529-013115692973
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2004;3(5):391–403. doi:10.1517/14740338.3.5.39115335295
   PubMedGoogle Scholar
• Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2004;5(9):1881–1886. doi:10.1517/14656566.5.9.188115330726
   PubMed Web of Science ®Google Scholar
• Reveille JD. 57 – Spondyloarthritis, in Clinical Immunology. Fifth Rich RR, et al., Editors, London: Content Repository Only; 2019:769–787.
   Google Scholar
• Skalska U, Kozakiewicz A, Maśliński W, Jurkowska M. HLA-B27 detection – comparison of genetic sequence-based method and flow cytometry assay. Reumatologia. 2015;53(2):74–78. doi:10.5114/reum.2015.5150627407231
   PubMedGoogle Scholar
• Khan MA. Polymorphism of HLA-B27: 105 subtypes currently known. Curr Rheumatol Rep. 2013;15(10):362. doi:10.1007/s11926-013-0362-y23990399
   PubMedGoogle Scholar
• Rysnik O, McHugh K, van Duivenvoorde L, et al. Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue. J Autoimmun. 2016;70:12–21. doi:10.1016/j.jaut.2016.03.00927036372
   PubMed Web of Science ®Google Scholar
• Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev. 2010;233(1):181–202. doi:10.1111/j.0105-2896.2009.00865.x20193000
   PubMedGoogle Scholar
• Guiliano DB, Fussell H, Lenart I, et al. Endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 1 targets misfolded HLA–B27 dimers for endoplasmic reticulum-associated degradation. Arthritis Rheumatol. 2014;66(11):2976–2988. doi:10.1002/art.3880925132672
   PubMed Web of Science ®Google Scholar
• Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186(4):2672–2680. doi:10.4049/jimmunol.100265321248258
   PubMed Web of Science ®Google Scholar
• Ridley A, Hatano H, Wong-Baeza I, et al. Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA–B27 licenses pathogenic T cell differentiation in spondyloarthritis. Arthritis Rheumatol. 2016;68(4):901–914. doi:10.1002/art.3951526841353
   PubMed Web of Science ®Google Scholar
• The Australo-Anglo-American Spondyloarthritis, C., et al.Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.Nat Genet.2010;42(p):123. doi:10.1038/ng.51320062062
   PubMedGoogle Scholar
• Saveanu L, Carroll O, Lindo V, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol. 2005;6:689. doi:10.1038/ni120815908954
   PubMed Web of Science ®Google Scholar
• Chang S-C, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci U S A. 2005;102(47):17107–17112. doi:10.1073/pnas.050072110216286653
   PubMed Web of Science ®Google Scholar
• Chen L, Ridley A, Hammitzsch A, et al. Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. Ann Rheum Dis. 2016;75(5):916–923. doi:10.1136/annrheumdis-2014-20699626130142
   PubMed Web of Science ®Google Scholar
• García-Medel N, Sanz-Bravo A, Van Nguyen D, et al. Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA-B27 in vivo. Mol Cell Proteomics. 2012;11(11):1416–1429. doi:10.1074/mcp.M112.01958822918227
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz J-P, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304–305. doi:10.1016/j.jbspin.2006.11.00517369068
   PubMed Web of Science ®Google Scholar
• Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269–273. doi:10.1007/s10067-010-1647-421161669
   PubMed Web of Science ®Google Scholar
• Gracey E, Yao Y, Green B, et al. Sexual dimorphism in the Th17 signature of ankylosing spondylitis. Arthritis Rheumatol. 2016;68(3):679–689. doi:10.1002/art.3946426473967
   PubMed Web of Science ®Google Scholar
• Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010;125(2, Supplement 2)):S24–S32. doi:10.1016/j.jaci.2009.07.01619932920
   PubMedGoogle Scholar
• Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol. 2014;57(1):2–11. doi:10.1016/j.molimm.2013.06.01323916070
   PubMed Web of Science ®Google Scholar
• Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family – balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76(1):25–37. doi:10.1016/j.cyto.2015.06.01726185894
   PubMed Web of Science ®Google Scholar
• Loo FAJVD, Joosten LAB, Van Lent PLEM, Arntz OJ, Van Den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 1995;38(2):164–172. doi:10.1002/(ISSN)1529-01317848306
   PubMedGoogle Scholar
• DANIS VA, MILLINGTON M, HYLAND VJ, GRENNAN D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clinical & Experimental Immunology. 1995;99(2):303–310. doi:10.1111/(ISSN)1365-22497851026
   PubMedGoogle Scholar
• Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10(1):411–452. doi:10.1146/annurev.iy.10.040192.0022111590993
   PubMedGoogle Scholar
• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38(4):499–505. doi:10.1002/(ISSN)1529-01317718003
   PubMed Web of Science ®Google Scholar
• Duivenvoorde LMV, Ambarus CA, Masdar H, et al. A2.15 relative overexpression of transmembrane versus soluble TNF in human and experimental spondyloarthritis. Ann Rheum Dis. 2013;72(Suppl 1):A9–A10. doi:10.1136/annrheumdis-2013-203215.15
   Google Scholar
• Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today. 1993;14(7):349–352. doi:10.1016/0167-5699(93)90234-C8363724
   PubMedGoogle Scholar
• Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195–3199. doi:10.1073/pnas.94.7.31959096369
   PubMed Web of Science ®Google Scholar
• El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. SpringerPlus. 2016;5(1):1508. doi:10.1186/s40064-016-3197-y27652081
   PubMedGoogle Scholar
• Mahmoudi M, Jamshidi AR, Amirzargar AA, et al. Association between endoplasmic reticulum aminopeptidase-1 (ERAP-1) and susceptibility to ankylosing spondylitis in Iran. Iran J Allergy Asthma Immunol. 2012;11(4);294–300.23264405
   PubMedGoogle Scholar
• Bettencourt BF, Rocha FL, Alves H, et al. Protective effect of an ERAP1 haplotype in ankylosing spondylitis: investigating non-MHC genes in HLA-B27-positive individuals. Rheumatology. 2013;52(12):2168–2176. doi:10.1093/rheumatology/ket26924046467
   PubMed Web of Science ®Google Scholar
• Haroon N, Tsui FWL, Chiu B, Tsui HW, Inman RD. Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. J Rheumatol. 2010;37(9):1907–1910. doi:10.3899/jrheum.10001920595269
   PubMedGoogle Scholar
• Hacquard‐Bouder C, Falgarone G, Bosquet A, et al. Defective costimulatory function is a striking feature of antigen‐presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy. Arthritis Rheum. 2004;50(5):1624–1635. doi:10.1002/(ISSN)1529-013115146433
   PubMedGoogle Scholar
• Hacquard‐Bouder C, Chimenti M-S, Giquel B, et al. Alteration of antigen‐independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA–B27. Arthritis Rheum. 2007;56(5):1478–1489. doi:10.1002/(ISSN)1529-013117469106
   PubMedGoogle Scholar
• Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis‐prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64(1):110–120. doi:10.1002/art.3332121905004
   PubMedGoogle Scholar
• Pan F, Barbi J, Pardoll DM. Hypoxia-inducible factor 1: a link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology. 2012;1(4):510–515. doi:10.4161/onci.1945722754770
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453:106. doi:10.1038/nature0688118362914
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Mackay CR, O’Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nature Rev Immunol. 2009;9:811. doi:10.1038/nri265419809471
   PubMed Web of Science ®Google Scholar
• El-Behi M, Ciric B, Dai H, et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6):568–575. doi:10.1038/ni.203121516111
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Höhler T. Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol. 2001;13(4):250–254.11555724
   PubMed Web of Science ®Google Scholar
• Benjamin M, McGONAGLE D. Basic concepts of enthesis biology and immunology. J Rheumatol Suppl. 2009;83:12–13. doi:10.3899/jrheum.09021119661528
   PubMedGoogle Scholar
• Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D. Microdamage and altered vascularity at the enthesis–bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum. 2007;56(1):224–233. doi:10.1002/(ISSN)1529-013117195226
   PubMedGoogle Scholar
• Costello M-E, Robinson PC, Benham H, Brown MA. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;29(2):202–212. doi:10.1016/j.berh.2015.08.00126362739
   PubMedGoogle Scholar
• Khan MA, van Der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA‐B27 positive ankylosing spondylitis patients. Arthritis Rheum. 1985;28(1):40–43. doi:10.1002/(ISSN)1529-01313871329
   PubMedGoogle Scholar
• McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ. 2006;333(7568):581–585. doi:10.1136/bmj.38954.689583.DE16974012
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(suppl 3):iii8–iii18. doi:10.1136/ard.61.suppl_3.iii812381506
   PubMedGoogle Scholar
• Spoorenberg A, Dougados M, Mielants H. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999;26(4):980–984.10229432
   PubMed Web of Science ®Google Scholar
• Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol. 1999;26(4):966–970.10229429
   PubMed Web of Science ®Google Scholar
• Underwood M, Dawes P. Inflammatory back pain in primary care. Rheumatology. 1995;34(11):1074–1077. doi:10.1093/rheumatology/34.11.1074
   Web of Science ®Google Scholar
• Dougados M, Linden SVD, Juhlin R, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–1227. doi:10.1002/(ISSN)1529-01311930310
   PubMed Web of Science ®Google Scholar
• Wong RS. Disease-modifying effects of long-term and continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) in Spondyloarthritis. Adv Pharmacol Sci. 2019;2019.
   Web of Science ®Google Scholar
• Nunes GPS,  Cunha PDS, Bosco DPD, Ribeiro SLE. Challenging management of hepatitis B infection in ankylosing spondylitis patients in an endemic area during immunosuppressive therapy. Rev Soc Bras Med Trop. 2019;52.
   Web of Science ®Google Scholar
• Kroon FP, van der Burg LRA, Ramiro S, et al. Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a cochrane review. J Rheumatol. 2016;43(3):607–617. doi:10.3899/jrheum.15072126834216
   PubMed Web of Science ®Google Scholar
• Evans DM, Spencer CCA, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43(8):761. doi:10.1038/ng.87321743469
   PubMed Web of Science ®Google Scholar
• Dougados M, Béhier J-M, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2–specific inhibitor, in the treatment of ankylosing spondylitis: a six‐week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001;44(1):180–185. doi:10.1002/(ISSN)1529-013111212158
   PubMedGoogle Scholar
• Coxib and traditional NSAID Trialists (CNT) Collaboration, Bhala N, et al. Vascular and Upper Gastrointestinal Effects of Non-steroidal Anti-inflammatory Drugs: Meta-analyses of Individual Participant Data from Randomised Trials. Lancet 2013 Aug 31;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9.
   Google Scholar
• Dougados M, Gueguen A, Nakache JP, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999;38(3):235–244. doi:10.1093/rheumatology/38.3.23510325662
   PubMed Web of Science ®Google Scholar
• Wanders A, Heijde DVD, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–1765. doi:10.1002/(ISSN)1529-013115934081
   PubMed Web of Science ®Google Scholar
• Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438–1443. doi:10.1136/annrheumdis-2015-20789726242443
   PubMed Web of Science ®Google Scholar
• Moon K-H, Kim Y-T. Medical treatment of ankylosing spondylitis. Hip Pelvis. 2014;26(3):129–135. doi:10.5371/hp.2014.26.3.12927536570
   PubMedGoogle Scholar
• Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409–416. doi:10.7326/M14-247026258401
   PubMed Web of Science ®Google Scholar
• Rademacher J, Poddubnyy D. Emerging drugs for the treatment of axial spondyloarthritis. Expert Opin Emerg Drugs. 2018;23(1):83–96. doi:10.1080/14728214.2018.144571929475394
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Jamshidi AR, Mahmoudi M, et al. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I/II clinical trial. Int Immunopharmacol. 2018;54:112–117. doi:10.1016/j.intimp.2017.11.00329127910
   PubMed Web of Science ®Google Scholar
• Emkey R, Rosenthal N, Wu S-C, Jordan D, Kamin M. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31(1):150–156.14705234
   PubMed Web of Science ®Google Scholar
• Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol. 2004;31(12):2454–2463.15570651
   PubMed Web of Science ®Google Scholar
• Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–545. doi:10.1016/s0002-9343(03)00116-512753877
   PubMed Web of Science ®Google Scholar
• Chang J-K, Yu C-T, Lee M-Y, et al. Tramadol/acetaminophen combination as add-on therapy in the treatment of patients with ankylosing spondylitis. Clin Rheumatol. 2013;32(3):341–347. doi:10.1007/s10067-012-2125-y23192419
   PubMed Web of Science ®Google Scholar
• Farrouq Mahmood PH. Ankylosing spondylitis: a review. Eur Med J. 2017;2(4):134–139.
   Google Scholar
• Ryall NH, Helliwell P. A critical review of ankylosing spondylitis. Crit Rev™ Phys Rehabil Med. 1998;10:3.
   Google Scholar
• sailaja AK. An overall review on ankylosing spondylitis. Int J Current Pharm Sci. 2014;1(1):1–5.
   Google Scholar
• Xie J, Fan Z, Li Y, et al. Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy. Int J Nanomedicine. 2018;13:1381–1398. doi:10.2147/IJN.S15231229563794
   PubMed Web of Science ®Google Scholar
• Nosrati H, Salehiabar M, Davaran S, Danafar H, Manjili HK. Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells. Drug Dev Ind Pharm. 2018;44(6):886–894. doi:10.1080/03639045.2017.1417422
   PubMed Web of Science ®Google Scholar
• Abdelrady H, Hathout RM, Osman R, Saleem I, Mortada ND. Exploiting gelatin nanocarriers in the pulmonary delivery of methotrexate for lung cancer therapy. EurJ Pharm Sci. 2019;133:115–126. doi:10.1016/j.ejps.2019.03.01630905615
   PubMed Web of Science ®Google Scholar
• Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419–421. doi:10.1136/ard.2006.05409816901959
   PubMed Web of Science ®Google Scholar
• Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014;11.
   Web of Science ®Google Scholar
• Xue H-X, Fu W-Y, Cui H-D, Yang -L-L, Zhang N, Zhao L-J. High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis. Neural Regener Res. 2015;10(5):814–818. doi:10.4103/1673-5374.156988
   PubMed Web of Science ®Google Scholar
• Wei J-C-C, Chan TW, Lin H-S, Huang F, Chou C-T. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol. 2003;30(12):2627–2631.14719205
   PubMed Web of Science ®Google Scholar
• Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1.
   Web of Science ®Google Scholar
• Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DTY. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2002;47(3):249–254. doi:10.1002/(ISSN)1529-0131
   Web of Science ®Google Scholar
• Nabeel AI, Moawed FSM, Hassan H. Immunomodulatory effect of new quinolone derivative against cisplatin/gamma radiation-induced renal and brain toxicity in mice. J Photochem Photobiol B. 2018;184:54–60. doi:10.1016/j.jphotobiol.2018.05.01329803073
   PubMed Web of Science ®Google Scholar
• Öğrendik M. Treatment of Ankylosing Spondylitis with Moxifloxacin. South Med Assoc. 2007;100(4):366–370. doi:10.1097/SMJ.0b013e31802fa2a8
   PubMed Web of Science ®Google Scholar
• Öğrendik M. Treatment of ankylosing spondylitis with co-amoxiclav. Clin Exp Pharmacol Physiol. 2018;45(7):742–744. doi:10.1111/1440-1681.1295229676028
   PubMedGoogle Scholar
• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–2574. doi:10.1056/NEJMra140618227355535
   PubMed Web of Science ®Google Scholar
• Gratacós J, Collado A, Filella X, et al.. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Rheumatology. 1994;33(10):927–931. doi:10.1093/rheumatology/33.10.927
   Web of Science ®Google Scholar
• Baraliakos X, et al. Persistent clinical efficacy and excellent safety over 5 years of treatment with the anti-TNF alpha agent infliximab in patients with ankylosing spondylitis In: Arthritis and Rheumatism. Hoboken, NJ: Wiley-Liss Div John Wiley & Sons Inc; 2006. doi:10.1136/ard.2007.075879
   Google Scholar
• Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period. Arthritis Care Res. 2008;59(9):1270–1278. doi:10.1002/art.v59:9
   Web of Science ®Google Scholar
• Van der Heijde D, et al. Long-term adalimumab treatment reduces signs and symptoms in ankylosing spondylitis (AS) patients – results from the ATLAS trial In: Leiden University Medical Center, editor. Annals of the Rheumatic Diseases. London, UK: BMJ Publishing Group British Med Assoc House; 2006.
   Google Scholar
• Braun J, Landewé R, Hermann K-GA, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54(5):1646–1652. doi:10.1002/(ISSN)1529-013116646033
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. Ann Rheum Dis. 2005;64(10):1462–1466. doi:10.1136/ard.2004.03347215778240
   PubMed Web of Science ®Google Scholar
• Haibel H, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology. 2005;44(12):1525–1530. doi:10.1093/rheumatology/kei04616091396
   PubMedGoogle Scholar
• Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–3236. doi:10.1002/(ISSN)1529-013114613288
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451–471. doi:10.1016/j.berh.2006.03.01016777576
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos AA. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis. 2007;66(2):270–271. doi:10.1136/ard.2006.05873517068063
   PubMedGoogle Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333. doi:10.1053/j.gastro.2005.11.03016472588
   PubMed Web of Science ®Google Scholar
• Markham A, Lamb HM. Infliximab. Drugs. 2000;59(6):1341–1359. doi:10.2165/00003495-200059060-0001010882166
   PubMed Web of Science ®Google Scholar
• Cook DA. J.B.D., D.C. Gallagher. Etanercept Rheumatoid Arthritis Drugs R & D. 1999;1(1):75–77.
   Google Scholar
• Toussirot É, Wendling D. Recent progress in ankylosing spondylitis treatment. Expert Opin Pharmacother. 2003;4(1):1–12. doi:10.1517/14656566.4.1.112517239
   PubMedGoogle Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346–354. doi:10.1136/annrheumdis-2015-20878327117698
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–363. doi:10.1136/annrheumdis-2015-20878627130908
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665–670. doi:10.1136/ard.2003.01638615037444
   PubMed Web of Science ®Google Scholar
• Liu W, Wu Y-H, Zhang L, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8(10):17362–17376.26770328
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070–1077. doi:10.1136/annrheumdis-2016-20973027965257
   PubMed Web of Science ®Google Scholar
• Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-23 and Th17 disease in inflammatory arthritis. J Clin Med. 2017;6:9.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50–55.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active Ankylosing Spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken). 2017;69(7):1020–1029. doi:10.1002/acr.2323328235249
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285. doi:10.1186/s13075-017-1490-y29273067
   PubMed Web of Science ®Google Scholar
• El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311. doi:10.1111/ajg.2006.101.issue-216454836
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076. doi:10.1038/nm.281722772566
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789. doi:10.1016/S0140-6736(13)60594-223769296
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann K-GA, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–823. doi:10.1136/annrheumdis-2013-20424824389297
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Wagner F, Kivitz AJ, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor- and interleukin-17-targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69(12):2283–2291. doi:10.1002/art.4031928941216
   PubMed Web of Science ®Google Scholar
• Genovese MC, Weinblatt ME, Mease PJ, et al. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford). 2018;57(11):1972–1981. doi:10.1093/rheumatology/key17330032191
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–1057. doi:10.1136/annrheumdis-2013-20496324550171
   PubMed Web of Science ®Google Scholar
• 6 daily stretches for ankylosing spondylitis that can help ease pain. Available from: https://creakyjoints.org/diet-exercise/ankylosing-spondylitis-stretches-exercises/ Accessed September 4, 2019.
   Google Scholar
• American College of Rheumatology Releases New Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis Treatment Recommendations; 2015 Available from: https://www.rheumatology.org/About-Us/Newsroom/Press-Releases/ID/679 Accessed September 4, 2019.
   Google Scholar
• Versus Arthritis. What is ankylosing spondylitis (AS)?. 2015 Available from: https://www.versusarthritis.org/about-arthritis/conditions/ankylosing-spondylitis/. Accessed September 4, 2019.
   Google Scholar
• Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol. 1985;24(3):242–249. doi:10.1093/rheumatology/24.3.2423160423
   PubMedGoogle Scholar
• Jacobs WB, Fehlings MG. Ankylosing spondylitis and spinal cord injury: origin, incidence, management, and avoidance. Neurosurg Focus. 2008;24(1):E12. doi:10.3171/FOC/2008/24/1/E12
   PubMed Web of Science ®Google Scholar
• Bron JL, de Vries MK, Snieders MN, van der Horst-Bruinsma IE, van Royen BJ. Discovertebral (Andersson) lesions of the spine in ankylosing spondylitis revisited. Clin Rheumatol. 2009;28(8):883–892. doi:10.1007/s10067-009-1151-x19294478
   PubMedGoogle Scholar
• Britto NMF, Renor BS, Ghizoni E, Tedeschi H, Joaquim AF. Spine surgery in patients with ankylosing spondylitis. Rev Assoc Med Bras 2018;64(4):379–383. doi:10.1590/1806-9282.64.04.379
   Google Scholar
• Lu MC, Koo M, Lai NS. Incident spine surgery in patients with ankylosing spondylitis: a secondary cohort analysis of a nationwide, population-based health claims database. Arthritis Care Res (Hoboken). 2018;70(9):1416–1420. doi:10.1002/acr.2347829193835
   PubMedGoogle Scholar
• Kurucan E, Bernstein DN, Mesfin A. Surgical management of spinal fractures in ankylosing spondylitis. J Spine Surg. 2018;4(3):501–508. doi:10.21037/jss.2018.06.1530547111
   PubMedGoogle Scholar
• Mountziaris PM, Kramer PR, Mikos AG. Emerging intra-articular drug delivery systems for the temporomandibular joint. Methods. 2009;47(2):134–140. doi:10.1016/j.ymeth.2008.09.00118835358
   PubMedGoogle Scholar
• Leone G, Fini M, Torricelli P, Giardino R, Barbucci R. An amidated carboxymethylcellulose hydrogel for cartilage regeneration. J Mater Sci. 2008;19(8):2873–2880. doi:10.1007/s10856-008-3412-7
   Web of Science ®Google Scholar
• Huang Y-C, Tsai S-K, Huang C-H, et al. Intravenous tenoxicam reduces uterine cramps after Cesarean delivery. Can J Anesthesia. 2002;49(4):384–387. doi:10.1007/BF03017327
   PubMed Web of Science ®Google Scholar
• Mohammad IS, He W, Yin L. A smart paclitaxel-disulfiram nanococrystals for efficient MDR reversal and enhanced apoptosis. Pharm Res. 2018;35(4):77. doi:10.1007/s11095-018-2370-029488114
   PubMedGoogle Scholar
• Mohammad IS, He W, Yin L. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 2018;100:335–348. doi:10.1016/j.biopha.2018.02.03829453043
   PubMed Web of Science ®Google Scholar
• Mohammad IS, Hu H, Yin L, He W. Drug nanocrystals: fabrication methods and promising therapeutic applications. Int J Pharm. 2019;562:187–202. doi:10.1016/j.ijpharm.2019.02.04530851386
   PubMedGoogle Scholar
• Mohammad IS, Teng C, Chaurasiya B, Yin L, Wu C, He W. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer. Int J Pharm. 2019;557:304–313. doi:10.1016/j.ijpharm.2018.12.06730599232
   PubMedGoogle Scholar
• DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(4):548–564. doi:10.1002/wnan.132925641955
   PubMed Web of Science ®Google Scholar
• Johnson BM, Junkins RD, Ting JPY. A spike in inflammation. Nat Nanotechnol. 2018;13(11):980–981. doi:10.1038/s41565-018-0292-y30374158
   PubMedGoogle Scholar
• Guan S, Munder A, Hedtfeld S, et al. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019;14(3):287–297. doi:10.1038/s41565-018-0358-x30692673
   PubMed Web of Science ®Google Scholar
• Chevalier X. Intraarticular treatments for osteoarthritis: new perspectives. Curr Drug Targets. 2010;11(5):546–560.20199394
   PubMed Web of Science ®Google Scholar
• Bhardwaj U, Burgess DJ. Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone. Int J Pharm. 2010;388(1):181–189. doi:10.1016/j.ijpharm.2010.01.00320079409
   PubMedGoogle Scholar
• Zhang Z, Huang G. Micro- and nano-carrier mediated intra-articular drug delivery systems for the treatment of osteoarthritis. J Nanotechnol. 2012;2012.
   Google Scholar
• Elron-Gross I, Glucksam Y, Margalit R. Liposomal dexamethasone–diclofenac combinations for local osteoarthritis treatment. Int J Pharm. 2009;376(1):84–91. doi:10.1016/j.ijpharm.2009.04.02519409466
   PubMedGoogle Scholar
• Srinath P, Vyas SP, Diwan PV. Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm. 2000;26(3):313–321. doi:10.1081/DDC-10010035910738648
   PubMed Web of Science ®Google Scholar
• Gottschalk O, Metz P, Dao Trong ML, et al. Therapeutic effect of methotrexate encapsulated in cationic liposomes (EndoMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo. Scand J Rheumatol. 2015;44(6):456–463. doi:10.3109/03009742.2015.103044826114440
   PubMed Web of Science ®Google Scholar
• Alekseeva AA, Moiseeva E, Onishchenko N, et al. Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma. Int J Nanomedicine. 2017;12:3735. doi:10.2147/IJN28553111
   PubMed Web of Science ®Google Scholar
• Gaidukevich SK, Mikulovich YL, Smirnova TG, et al. Antibacterial effects of liposomes containing phospholipid cardiolipin and fluoroquinolone levofloxacin on mycobacterium tuberculosis with extensive drug resistance. Bull Exp Biol Med. 2016;160(5):675–678. doi:10.1007/s10517-016-3247-z27021087
   PubMedGoogle Scholar
• Vázquez JL, Montero MT, Trias J, Hernàndez-Borrell J. 6-Fluoroquinolone–liposome interactions: fluorescence quenching study using iodide. Int J Pharm. 1998;171(1):75–86. doi:10.1016/S0378-5173(98)00154-9
   Google Scholar
• Grancelli A, Morros A, Cabañas ME, et al. Interaction of 6-fluoroquinolones with dipalmitoylphosphatidylcholine monolayers and liposomes. Langmuir. 2002;18(24):9177–9182. doi:10.1021/la025837h
   Web of Science ®Google Scholar
• Furneri PM, Fresta M, Puglisi G, Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000;44(9):2458–2464. doi:10.1128/aac.44.9.2458-2464.200010952595
   PubMed Web of Science ®Google Scholar
• Ten Hagen TLM, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma-bearing rats. Int J Cancer. 2000;87(6):829–837. doi:10.1002/1097-0215(20000915)87:6<829::aid-ijc12>3.0.co;2-c10956394
   PubMedGoogle Scholar
• Kim DW, Andres ML, Li J, et al. Liposome-encapsulated tumor necrosis factor-α enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res. 2001;21(11):885–897. doi:10.1089/10799900175328949711747620
   PubMedGoogle Scholar
• Kedar E, Palgi O, Golod G, Babai I, Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother. 1997;20(3):180–193.9181456
   PubMed Web of Science ®Google Scholar
• Meka RR, Venkatesha SH, Moudgil KD. Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis. J Controlled Release. 2018;286:279–288. doi:10.1016/j.jconrel.2018.08.007
   PubMed Web of Science ®Google Scholar
• Lin S-Y, Chen KS, Teng HH, Li MJ. In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul. 2000;17(5):577–586. doi:10.1080/02652040041763011038117
   PubMed Web of Science ®Google Scholar
• Tunçay M, Caliş S, Kaş HS, Ercan MT, Peksoy I, Hincal AA. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int J Pharm. 2000;195(1):179–188.10675695
   PubMedGoogle Scholar
• Skoutakis VA, Carter CA, Mickle TR, et al. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm. 1988;22(11):850–859. doi:10.1177/1060028088022011023069424
   PubMedGoogle Scholar
• Saravanan M, Bhaskar K, Maharajan G, Pillai KS. Development of gelatin microspheres loaded with diclofenac sodium for intra-articular administration. J Drug Target. 2011;19(2):96–103. doi:10.3109/1061186100373397920380621
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao M, Yu C, et al. Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. Int J Nanomedicine. 2017;12:6735. doi:10.2147/IJN28932117
   PubMed Web of Science ®Google Scholar
• Zhang H, Li X, Ding J, et al. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013;441(1):261–268. doi:10.1016/j.ijpharm.2012.11.03423194884
   PubMedGoogle Scholar
• Iqbal S, Du X, Wang J, Li H, Yuan Y, Wang J. Surface charge tunable nanoparticles for TNF-α siRNA oral delivery for treating ulcerative colitis. Nano Res. 2018;11(5):2872–2884. doi:10.1007/s12274-017-1918-3
   Web of Science ®Google Scholar
• Davis SM, Reichel D, Bae Y, Pennypacker KR. Leukemia inhibitory factor-loaded nanoparticles with enhanced cytokine metabolic stability and anti-inflammatory activity. Pharm Res. 2018;35(1):6. doi:10.1007/s11095-017-2282-429294201
   PubMedGoogle Scholar
• Peppas N, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27–46.10840191
   PubMed Web of Science ®Google Scholar
• Barbucci R, Lamponi S, Borzacchiello A, et al. Hyaluronic acid hydrogel in the treatment of osteoarthritis. Biomaterials. 2002;23(23):4503–4513. doi:10.1016/s0142-9612(02)00194-112322970
   PubMed Web of Science ®Google Scholar
• Hu X-B, Kang -R-R, Tang -T-T, et al. Topical delivery of 3,5,4′-trimethoxy-trans-stilbene-loaded microemulsion-based hydrogel for the treatment of osteoarthritis in a rabbit model. Drug Deliv Transl Res. 2019;9(1):357–365. doi:10.1007/s13346-018-00604-z30430453
   PubMed Web of Science ®Google Scholar
• Ahmad U, Sohail M, Ahmad M, et al. Chitosan based thermosensitive injectable hydrogels for controlled delivery of loxoprofen: development, characterization and in-vivo evaluation. Int J Biol Macromol. 2019;129:233–245. doi:10.1016/j.ijbiomac.2019.02.03130738157
   PubMed Web of Science ®Google Scholar
• Dong L, Xia S, Chen H, Chen J, Zhang J. Spleen-specific suppression of TNF-α by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models. Biomaterials. 2009;30(26):4416–4426. doi:10.1016/j.biomaterials.2009.04.04519481251
   PubMedGoogle Scholar
• Robert M-C, Frenette M, Zhou C, et al. A drug delivery system for administration of anti-TNF-α antibody. Transl Vis Sci Technol. 2016;5(2):11. doi:10.1167/tvst.5.2.11
   PubMed Web of Science ®Google Scholar
• Zhang Z, Huang G. Intra-articular lornoxicam loaded PLGA microspheres: enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis. Drug Deliv. 2012;19(5):255–263. doi:10.3109/10717544.2012.70096222775466
   PubMed Web of Science ®Google Scholar
• Ko J-Y, Choi Y-J, Jeong G-J, Im G-I. Sulforaphane–PLGA microspheres for the intra-articular treatment of osteoarthritis. Biomaterials. 2013;34(21):5359–5368. doi:10.1016/j.biomaterials.2013.03.06623601658
   PubMedGoogle Scholar
• Bozdag S, Caliş S, Kaş HS, Ercan MT, Peksoy I, Hincal AA. In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. J Microencapsul. 2001;18(4):443–456. doi:10.1080/0265204001001864111428674
   PubMed Web of Science ®Google Scholar
• Elron-Gross I, Glucksam Y, Biton IE, Margalit R. A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI. J Controlled Release. 2009;135(1):65–70. doi:10.1016/j.jconrel.2008.12.005
   PubMed Web of Science ®Google Scholar
• Whitmire RE, Wilson DS, Singh A, Levenston ME, Murthy N, García AJ. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials. 2012;33(30):7665–7675. doi:10.1016/j.biomaterials.2012.06.10122818981
   PubMed Web of Science ®Google Scholar
• Dong J, Jiang D, Wang Z, Wu G, Miao L, Huang L. Intra-articular delivery of liposomal celecoxib–hyaluronate combination for the treatment of osteoarthritis in rabbit model. Int J Pharm. 2013;441(1):285–290. doi:10.1016/j.ijpharm.2012.11.03123194887
   PubMedGoogle Scholar
• Hui JH, Chan S-W, Li J, et al. Intra-articular delivery of chondroitin sulfate for the treatment of joint defects in rabbit model. J Mol Histol. 2007;38(5):483–489. doi:10.1007/s10735-007-9120-717653606
   PubMedGoogle Scholar